×
S&P 500   3,832.02 (-1.75%)
DOW   31,025.50 (-1.31%)
QQQ   284.40 (-2.75%)
AAPL   138.00 (-2.58%)
MSFT   257.44 (-2.81%)
META   162.97 (-3.85%)
GOOGL   2,252.48 (-2.77%)
AMZN   107.54 (-5.02%)
TSLA   701.01 (-4.59%)
NVDA   160.36 (-4.94%)
NIO   22.27 (-2.96%)
BABA   116.69 (-1.72%)
AMD   80.70 (-6.34%)
MU   58.24 (-0.92%)
CGC   3.58 (-5.54%)
T   20.62 (-0.77%)
GE   65.50 (-1.81%)
F   11.83 (-1.74%)
DIS   96.43 (-0.19%)
AMC   13.60 (-3.75%)
PFE   50.46 (-2.74%)
PYPL   71.82 (-5.43%)
NFLX   181.69 (-3.94%)
S&P 500   3,832.02 (-1.75%)
DOW   31,025.50 (-1.31%)
QQQ   284.40 (-2.75%)
AAPL   138.00 (-2.58%)
MSFT   257.44 (-2.81%)
META   162.97 (-3.85%)
GOOGL   2,252.48 (-2.77%)
AMZN   107.54 (-5.02%)
TSLA   701.01 (-4.59%)
NVDA   160.36 (-4.94%)
NIO   22.27 (-2.96%)
BABA   116.69 (-1.72%)
AMD   80.70 (-6.34%)
MU   58.24 (-0.92%)
CGC   3.58 (-5.54%)
T   20.62 (-0.77%)
GE   65.50 (-1.81%)
F   11.83 (-1.74%)
DIS   96.43 (-0.19%)
AMC   13.60 (-3.75%)
PFE   50.46 (-2.74%)
PYPL   71.82 (-5.43%)
NFLX   181.69 (-3.94%)
S&P 500   3,832.02 (-1.75%)
DOW   31,025.50 (-1.31%)
QQQ   284.40 (-2.75%)
AAPL   138.00 (-2.58%)
MSFT   257.44 (-2.81%)
META   162.97 (-3.85%)
GOOGL   2,252.48 (-2.77%)
AMZN   107.54 (-5.02%)
TSLA   701.01 (-4.59%)
NVDA   160.36 (-4.94%)
NIO   22.27 (-2.96%)
BABA   116.69 (-1.72%)
AMD   80.70 (-6.34%)
MU   58.24 (-0.92%)
CGC   3.58 (-5.54%)
T   20.62 (-0.77%)
GE   65.50 (-1.81%)
F   11.83 (-1.74%)
DIS   96.43 (-0.19%)
AMC   13.60 (-3.75%)
PFE   50.46 (-2.74%)
PYPL   71.82 (-5.43%)
NFLX   181.69 (-3.94%)
S&P 500   3,832.02 (-1.75%)
DOW   31,025.50 (-1.31%)
QQQ   284.40 (-2.75%)
AAPL   138.00 (-2.58%)
MSFT   257.44 (-2.81%)
META   162.97 (-3.85%)
GOOGL   2,252.48 (-2.77%)
AMZN   107.54 (-5.02%)
TSLA   701.01 (-4.59%)
NVDA   160.36 (-4.94%)
NIO   22.27 (-2.96%)
BABA   116.69 (-1.72%)
AMD   80.70 (-6.34%)
MU   58.24 (-0.92%)
CGC   3.58 (-5.54%)
T   20.62 (-0.77%)
GE   65.50 (-1.81%)
F   11.83 (-1.74%)
DIS   96.43 (-0.19%)
AMC   13.60 (-3.75%)
PFE   50.46 (-2.74%)
PYPL   71.82 (-5.43%)
NFLX   181.69 (-3.94%)
NASDAQ:MGTX

MeiraGTx Stock Forecast, Price & News

$7.31
-0.23 (-3.05%)
(As of 06/28/2022 02:30 PM ET)
Add
Compare
Today's Range
$7.09
$7.53
50-Day Range
$6.80
$12.88
52-Week Range
$6.59
$24.89
Volume
6,722 shs
Average Volume
139,689 shs
Market Capitalization
$326.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00
30 days | 90 days | 365 days | Advanced Chart

Receive MGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MeiraGTx and its competitors with MarketBeat's FREE daily newsletter.

MGTX Stock Forecast (MarketRank)

Overall MarketRank

2.62 out of 5 stars

Medical Sector

83rd out of 1,436 stocks

Biological Products, Except Diagnostic Industry

12th out of 217 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -
MeiraGTx logo

About MeiraGTx (NASDAQ:MGTX)

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.

MGTX Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MGTX
Fax
N/A
Employees
287
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
6/28/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$30.00
High Stock Price Forecast
$46.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+310.4%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
2 Analysts

Profitability

Net Income
$-79.56 million
Net Margins
-224.55%
Pretax Margin
-224.55%

Debt

Sales & Book Value

Annual Sales
$37.70 million
Book Value
$4.17 per share

Miscellaneous

Free Float
38,764,000
Market Cap
$326.83 million
Optionable
Not Optionable
Beta
1.84














MeiraGTx Frequently Asked Questions

Should I buy or sell MeiraGTx stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MeiraGTx stock.
View analyst ratings for MeiraGTx
or view top-rated stocks.

What is MeiraGTx's stock price forecast for 2022?

2 equities research analysts have issued twelve-month price objectives for MeiraGTx's stock. Their MGTX stock forecasts range from $18.00 to $46.00. On average, they predict MeiraGTx's stock price to reach $30.00 in the next year. This suggests a possible upside of 310.4% from the stock's current price.
View analysts' price targets for MeiraGTx
or view top-rated stocks among Wall Street analysts.

How has MeiraGTx's stock price performed in 2022?

MeiraGTx's stock was trading at $23.74 at the start of the year. Since then, MGTX stock has decreased by 69.2% and is now trading at $7.31.
View the best growth stocks for 2022 here
.

When is MeiraGTx's next earnings date?

MeiraGTx is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for MeiraGTx
.

How were MeiraGTx's earnings last quarter?

MeiraGTx Holdings plc (NASDAQ:MGTX) announced its quarterly earnings results on Thursday, May, 12th. The company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.21. The firm had revenue of $5.63 million for the quarter, compared to the consensus estimate of $9.25 million. MeiraGTx had a negative trailing twelve-month return on equity of 47.01% and a negative net margin of 224.55%.
View MeiraGTx's earnings history
.

Who are MeiraGTx's key executives?

MeiraGTx's management team includes the following people:
  • Dr. Alexandria Forbes, CEO, Pres & Director (Age 57, Pay $3.05M) (LinkedIn Profile)
  • Mr. Richard Brian Giroux B.A., COO & CFO (Age 48, Pay $2.39M)
  • Dr. Robert K. Zeldin M.D., Chief Medical Officer (Age 59, Pay $1.1M)
  • Mr. Robert J. Wollin J.D., Gen. Counsel & Sec. (Age 45)
  • Dr. Stuart Naylor Ph.D., Chief Devel. Officer (Age 59)
  • Dr. Michel Michaelides M.D., Head of Clinical Ophthalmology
  • Ms. Christine Elise Sheehy, Sr. VP of Global Integration (Age 54)
  • Mr. Joel P. Brooks, Sr. VP of Fin. (Age 63)
  • Mr. Tim Randall, Sr. VP of Risk & Internal Controls
  • Dr. Alastair Leighton Ph.D., Sr. VP of Manufacturing & Supply Chain

What other stocks do shareholders of MeiraGTx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MeiraGTx investors own include AbbVie (ABBV), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Inovio Pharmaceuticals (INO), Kadmon (KDMN), Pfizer (PFE), VBI Vaccines (VBIV), Novavax (NVAX), Viking Therapeutics (VKTX) and Advanced Micro Devices (AMD).

When did MeiraGTx IPO?

(MGTX) raised $75 million in an IPO on Friday, June 8th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager.

What is MeiraGTx's stock symbol?

MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."

Who are MeiraGTx's major shareholders?

MeiraGTx's stock is owned by a variety of retail and institutional investors. Top institutional investors include Royce & Associates LP (1.47%), State Street Corp (1.20%), Rhenman & Partners Asset Management AB (1.12%), Dimensional Fund Advisors LP (0.90%), Prosight Management LP (0.85%) and Assenagon Asset Management S.A. (0.67%). Company insiders that own MeiraGTx stock include Alexandria Forbes, Elizabeth A Cook, Joel S Marcus, Life Sciences Maste Perceptive, Nicole Seligman, Richard Giroux, Robert J Wollin, Robert K Zeldin, Stuart Naylor and Thomas E Shenk.
View institutional ownership trends for MeiraGTx
.

Which institutional investors are selling MeiraGTx stock?

MGTX stock was sold by a variety of institutional investors in the last quarter, including Captrust Financial Advisors, Royce & Associates LP, Salem Investment Counselors Inc., UBS Group AG, TD Asset Management Inc., Jane Street Group LLC, Citigroup Inc., and Northern Trust Corp. Company insiders that have sold MeiraGTx company stock in the last two years include Alexandria Forbes, Elizabeth A Cook, Joel S Marcus, Richard Giroux, Stuart Naylor, and Thomas E Shenk.
View insider buying and selling activity for MeiraGTx
or view top insider-selling stocks.

Which institutional investors are buying MeiraGTx stock?

MGTX stock was purchased by a variety of institutional investors in the last quarter, including Prosight Management LP, Assenagon Asset Management S.A., Goldman Sachs Group Inc., Dimensional Fund Advisors LP, Alyeska Investment Group L.P., Rhenman & Partners Asset Management AB, Russell Investments Group Ltd., and Bank of America Corp DE. Company insiders that have bought MeiraGTx stock in the last two years include Robert J Wollin, and Robert K Zeldin.
View insider buying and selling activity for MeiraGTx
or or view top insider-buying stocks.

How do I buy shares of MeiraGTx?

Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MeiraGTx's stock price today?

One share of MGTX stock can currently be purchased for approximately $7.31.

How much money does MeiraGTx make?

MeiraGTx (NASDAQ:MGTX) has a market capitalization of $326.83 million and generates $37.70 million in revenue each year. The company earns $-79.56 million in net income (profit) each year or ($1.970010) on an earnings per share basis.

How many employees does MeiraGTx have?

MeiraGTx employs 287 workers across the globe.

How can I contact MeiraGTx?

MeiraGTx's mailing address is 450 East 29thStreet 14thFloor, NEW YORK NY, 10016. The official website for MeiraGTx is www.meiragtx.com. The company can be reached via phone at (646) 860-7985 or via email at [email protected].

This page (NASDAQ:MGTX) was last updated on 6/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.